100% of patients had $\leq 5^\circ$ of rotation at 1 to 6 months

- 91% of patients had $\leq 5^\circ$ of rotation at 24 to 48 hours
enVista TORIC Specifications
One-Piece Hydrophobic Acrylic IOL

SPECIFICATIONS

LENS CHARACTERISTICS

<table>
<thead>
<tr>
<th>Lens Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Power range</td>
<td>+6.0 to +30.0 D in 0.5-D increments</td>
</tr>
<tr>
<td>Cylinder powers—IOL plane</td>
<td>1.25 D, 2.00 D, 2.75 D, 3.50 D, 4.25 D, 5.00 D, 5.75 D</td>
</tr>
<tr>
<td>Cylinder powers—corneal plane</td>
<td>0.90 D, 1.40 D, 1.93 D, 2.45 D, 2.98 D, 3.50 D, 4.03 D</td>
</tr>
<tr>
<td>Optic body diameter</td>
<td>6.0 mm</td>
</tr>
<tr>
<td>Overall length with haptics</td>
<td>12.5 mm</td>
</tr>
<tr>
<td>Design</td>
<td>One-piece, aspheric optic</td>
</tr>
<tr>
<td>Material</td>
<td>Hydrophobic acrylic material with UV absorber</td>
</tr>
<tr>
<td>Refractive index</td>
<td>1.54 at 35°C</td>
</tr>
<tr>
<td>Edge design</td>
<td>360° posterior square edge</td>
</tr>
</tbody>
</table>

100% of patients had ≤ 5° of rotation at 1 to 6 months
91% of patients had ≤ 5° of rotation at 24 to 48 hours

OPTICAL BIOMETRY

- Suggested A-constant*: 119.1
- Theoretical AC depth*: 5.61 mm
- Surgeon factor*: 1.85

APPLANATION

- Suggested A-constant*: 118.7
- Theoretical AC depth*: 5.37 mm
- Surgeon factor*: 1.62

HAPTIC CHARACTERISTICS

- Design: Modified C-loop, step-vaulted

INSERTION INSTRUMENT

- Bausch + Lomb IOL Injector INJ100 Lens Model: MX60
- Medicel ACCUJECT 2.2† Lens Model: MX60T

enVista TORIC is not approved for sale in the United States.

*A-constant, ACD, and surgeon factor are estimates only. It is recommended that each surgeon develop his or her own values.

†Medicel ACCUJECT 2.2 IP Rev. 2.

INDICATIONS: Indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing corneal astigmatism in whom the cataractous lens has been removed by an extracapsular cataract extraction method. The lens is intended for placement in the capsular bag. WARNINGS: Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: 1. Recurrent severe anterior or posterior segment inflammation or events. 2. Patients in whom the intraocular lens may affect the ability to observe, diagnose, or treat posterior segment diseases. 3. Surgical difficulties at the time of cataract extraction, which might increase the potential for complications (eg, persistent bleeding, significant injury, damage, uncontrolled positive pressure, or significant vitreous prolapse or loss). 4. A distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is impossible. 5. Circumstances that would result in damage to the endothelium during implantation. 6. Suspected microbial infection. 7. Children under the age of 12 years are not suitable candidates for intraocular lenses. 8. Patients in whom neither the posterior capsule nor zonules are intact enough to provide support. PRECAUTIONS: Do not attempt to resterilize the lens or its components with any solution other than sterile balanced salt solution or sterile normal saline. Do not store the lens at a temperature greater than 43°C (110°F). DO NOT FREEZE. Do not autoclave the intraocular lens. Do not re-use the lens. It is intended for permanent implantation. If explanted, sterility and proper function cannot be assured. For complete physician labeling information, refer to the enVista® product package insert.

©2013 Bausch & Lomb Incorporated. ™ and ® are trademarks of Bausch & Lomb Incorporated or its affiliates. All other brand/product names are trademarks of their respective owners.